CoChat

Acute and Sustained Reductions in Loss of Meaning and Suicidal Ideation Following Psilocybin-Assisted Psychotherapy for Psychiatric and Existential Distress in Life-Threatening Cancer

Open access
Ross, Stephen, Agin-Liebes, Gabrielle, Lo, Sharon, Zeifman, Richard J., Ghazal, Leila, Benville, Julia, Franco Corso, Silvia, Bjerre Real, Christian, Guss, Jeffrey, Bossis, Anthony, Mennenga, Sarah E. · 2021 · ACS Pharmacology & Translational Science

The DOI matches its Crossref record; 81 of the 81 references it cites were found in a registry or an index.

Abstract

People with advanced cancer are at heightened risk of desire for hastened death (DHD), suicidal ideation (SI), and completed suicide. Loss of Meaning (LoM), a component of demoralization, can be elevated by a cancer diagnosis and predicts DHD and SI in this population. We completed a randomized controlled trial in which psilocybin-assisted psychotherapy (PAP) produced rapid and sustained improvements in depression, demoralization, and hopelessness in people with cancer. Converging epidemiologic and clinical trial findings suggests a potential antisuicidal effect of this treatment. To probe our hypothesis that PAP relieves SI through its beneficial impacts on depression and demoralization (LoM in particular), we performed secondary analyses assessing within- and between-group differences with regard to LoM and an SI composite score. Among participants with elevated SI at baseline, PAP was associated with within-group reductions in SI that were apparent as early as 8 h and persisted for 6.5 months postdosing. PAP also produced large reductions in LoM from baseline that were apparent 2 weeks after treatment and remained significant and robust at the 6.5 month and 3.2 and 4.5 year follow-ups. Exploratory analyses support our hypothesis and suggest that PAP may be an effective antisuicidal intervention following a cancer diagnosis due to its positive impact on hopelessness and demoralization and its effects on meaning-making in particular. These preliminary results implicate psilocybin treatment as a potentially effective alternative to existing antidepressant medications in patients with cancer that are also suicidal, and warrant further investigation in participants with elevated levels of depression and suicidality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/acsptsci.1c00020

Cites

81 of 81 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

1 more claim about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Robinson, 2015, A systematic review of the demoralization syndrome in individuals with progressive disease and cancer: a decade of research, J. Pain Symptom Manage., 49, 595, 10.1016/j.jpainsymman.2014.07.008 · DOI · Paper page
  2. Ross, 2021, Psilocybin

Cited by

See all 150

Metadata

Authors
Ross, S., Agin-Liebes, G., Lo, S., Zeifman, R. J., Ghazal, L., Benville, J., Franco Corso, S., Bjerre Real, C., Guss, J., Bossis, A., & Mennenga, S. E.
Affiliations
  • NYU Langone Health (US)
  • San Francisco General Hospital (US)
  • Pacific University Oregon (US)
  • Toronto Metropolitan University (CA)
  • Columbia University , , , , ,
  • Memorial Sloan Kettering Cancer Center , , , ,
Corresponding author
Ross, Stephen
Venue
ACS Pharmacology & Translational Science
Published
2021-03-18
Volume
4
Issue
2
Pages
553-562
ISSN
2575-9108 (ISSN-L)
OpenAlex
W3138429576
Cited by
139
References
80
Citations by year
2026: 14 · 2025: 33 · 2024: 40 · 2023: 22 · 2022: 24 · 2021: 6
FWCI
15.69
Type
journal article
Language
en
Open access
Locations
  • ACS Pharmacology & Translational Science (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Riverstyx Foundation
  • Clinical and Translational Science Institute, New York University
  • Heffter Research Institute
  • National Institute on Drug Abuse (T32DA007294, T32DA007250)
  • National Cancer Institute (P30CA008748)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Palliative and Oncologic Care
  • Health Sciences › Medicine › Oncology › Cancer survivorship and care
Keywords
psilocybin-assisted therapy, suicidal ideation, meaninglessness, demoralization, advanced cancer, depression, hopelessness, meaning-making, psychedelic therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.